{rfName}
Ne

Indexed in

Citations

19

Altmetrics

Share

January 5, 2026
Publications
>
Article
No

New clinical concepts after the ONTARGET trial

Publicated to: Expert Review of Cardiovascular Therapy. 9 (6): 685-689 - 2011-01-01 9(6), DOI: 10.1586/erc.11.52

Authors:

Ruilope, LM; Segura, J; Zamorano, JL
[+]

Affiliations

Hosp 12 Octubre, Hypertens Unit, Avda Cordoba S-N - Author
Hosp Clin San Carlos, Cardiovasc Inst - Author
Univ Autonoma Madrid - Author
See more

Abstract

Some aspects of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study are briefly commented on in this article. The three main topics of interest related to the study that require further analysis are the following: the influence of blood pressure control, and in particular, the target blood pressure for patients with established cardiovascular disease such as those admitted in the ONTARGET study, the renal aspects of the study, which are of great interest but do not adequately clarify, in particular, concerns over the dual blockade of the renin-angiotensin-aldosterone system (RAAS) with telmisartan and ramipril, and finally, and probably most importantly, the role of statins in the outcome of the study. A high percentage of patients receiving this type of therapy at the end of the study, which probably contributed to obtaining a residual risk similar to that in the Heart Outcomes Prevention Evaluation (HOPE) study in the absence of treatment with RAAS blockers in approximately two-thirds of patients included in the ONTARGET trial.
[+]

Keywords

AlbuminuriaDual blockade of the raas systemEgfrEstablished cardiovascular diseaseHigh cardiovascular riskRamiprilRenal functionReninangiotensinaldosterone systemResidual riskStatinsTelmisartan

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Expert Review of Cardiovascular Therapy due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2011, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Internal Medicine.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-05:

  • WoS: 9
  • Scopus: 10
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 10 (PlumX).
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Ruilope, LM) .

the author responsible for correspondence tasks has been Ruilope, LM.

[+]